Navidea Biopharmaceuticals IncNYSE American:NAVB
- LAST PRICE0.2900
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.2400/ 25
- Ask / Lots0.3500/ 1
- Open / Previous Close0.0000 / 0.2900
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NAVB |
|---|---|---|
| 09:32 ET | 32342 | 0.282 |
| 09:36 ET | 1000 | 0.281 |
| 09:38 ET | 2020 | 0.2798 |
| 09:39 ET | 1050 | 0.2799 |
| 09:41 ET | 4516 | 0.27 |
| 09:43 ET | 11772 | 0.260101 |
| 09:52 ET | 150 | 0.2601 |
| 09:57 ET | 1969 | 0.265 |
| 09:59 ET | 3200 | 0.2731 |
| 10:01 ET | 1400 | 0.2731 |
| 10:10 ET | 500 | 0.2764 |
| 10:15 ET | 4959 | 0.278101 |
| 10:21 ET | 225 | 0.28 |
| 10:39 ET | 900 | 0.280101 |
| 10:51 ET | 6849 | 0.28 |
| 11:11 ET | 1000 | 0.28 |
| 11:24 ET | 300 | 0.2761 |
| 11:42 ET | 766 | 0.2761 |
| 12:27 ET | 4151 | 0.276 |
| 12:30 ET | 18000 | 0.2979 |
| 01:42 ET | 3533 | 0.2802 |
| 01:44 ET | 100 | 0.28 |
| 01:51 ET | 1000 | 0.2844 |
| 02:06 ET | 807 | 0.28 |
| 02:15 ET | 300 | 0.2812 |
| 02:18 ET | 100 | 0.2811 |
| 02:38 ET | 1341 | 0.276 |
| 02:49 ET | 100 | 0.2851 |
| 02:58 ET | 1000 | 0.2869 |
| 03:27 ET | 1000 | 0.2977 |
| 03:48 ET | 963 | 0.2761 |
| 03:54 ET | 100 | 0.276 |
| 03:57 ET | 100 | 0.276 |
| 03:59 ET | 0 | 0.29 |
Mar 21, 2023
BRIEF-Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results, from 4:01PM ET on Tuesday Mar 21, 2023 by Thomson Reuters
4:01PM ET on Tuesday Mar 21, 2023 by Thomson ReutersNavidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results, from 4:01PM ET on Tuesday Mar 21, 2023 by Business Wire
4:01PM ET on Tuesday Mar 21, 2023 by Business Wire
Mar 15, 2023
Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update, from 7:30AM ET on Wednesday Mar 15, 2023 by Business Wire
7:30AM ET on Wednesday Mar 15, 2023 by Business Wire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Navidea Biopharmaceuticals Inc | 9.4M | -0.5x | --- |
Aslan Pharmaceuticals Ltd | 9.4M | -0.2x | --- |
ENDRA Life Sciences Inc | 9.3M | -0.6x | --- |
Neximmune Inc | 9.8M | -0.1x | --- |
Virax Biolabs Group Ltd | 9.0M | -4.7x | --- |
Theriva Biologics Inc | 9.8M | -0.5x | --- |
Company Information
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. Its business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. The Company has developed processes for producing the first two therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which targets activated CD206+ macrophages, and the Manocept dexamethasone (MAN-DEX) series, which inhibits the inflammatory activity of activated CD206+ macrophages.
Contact Information
- Headquarters
- SUITE 300, 425 METRO PLACE NORTHDUBLIN, OH, United States 43017
- Phone
- 614-793-7500
- Fax
- 614-793-7520
Executives
- Independent Chairman of the Board
- Alexander Cappello
- Vice Chairman of the Board
- John Scott
- Vice President - Finance and Administration
- Erika Eves
- Vice President - Operations
- Jeffrey Smith
- Chief Medical Officer
- Michael Rosol
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $9.4M |
|---|---|
Revenue (TTM) | $65.7K |
Shares Outstanding | 32.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.52 |
EPS | $-0.56 |
Book Value | $-0.26 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 142.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -21,399.47% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
